Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

Eli Lilly and Company LLY announced that its popular obesity drug, Zepbound (tirzepatide) demonstrated more weight loss than ...

That's according to new data from drug savings company GoodRx, which examined fill trends and spending patterns for weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. It offers ...

After a stellar FY24 performance, Natco Pharma’s stock has taken a hit. What’s next for the company as it faces crucial ...

WASHINGTON (Reuters) -U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more than 7 million people with Medicare and Medicaid ...

with the Food and Drug Administration approving a new class of weekly injectables like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound to treat obesity. People can lose as much as 15% to 25% ...

The drug isn’t approved for this use, but it may be helpful for weight loss. Ozempic comes as a solution inside an injection pen. You will ... Ozempic and Wegovy are both GLP-1 injections ...

These Catalent sites are already involved in Novo Nordisk manufacturing contracts, which are largely tied to ramping up supply of the firm’s obesity drug Wegovy. Novo Nordisk expects that ...

Dupixent is used to treat certain cases of: Dupixent comes as a single-dose prefilled syringe and a single-dose prefilled pen. You may receive ... see the dosage chart above.

Odds are you eligible for a prescription for semaglutide, the popular diabetes and weight loss drug better known by the brand names Ozempic and Wegovy. More than half of U.S. adults – 136.8 mill ...